Scarica l'app Stockscreener
13.51
0.00%
0.00
Pre-mercato:
13.36
-0.15
-1.11%
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
JPMorgan Chase & Co. Has $14.74 Million Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Is ORIC’s ESOP Shelf And Narrower Quarterly Loss Altering The Investment Case For ORIC (ORIC)? - simplywall.st
ORIC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Oric Pharmaceuticals, Inc. $ORIC Stake Raised by Royce & Associates LP - MarketBeat
Oric Pharmaceuticals Teases Key 2026 Catalysts, Phase 3 Plans for Prostate and Lung Cancer Drugs - MarketBeat
ORIC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Uncovering a 57% Upside Potential in Biotech - DirectorsTalk Interviews
ORIC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ORIC Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Sell: Dominic Piscitelli Sells 52,000 Shares of ORIC Pha - GuruFocus
Dominic Piscitelli Sells 52,000 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat
Oric Pharmaceuticals Insider Sold Shares Worth $702,686, According to a Recent SEC Filing - marketscreener.com
Oric Pharmaceuticals CFO Dominic Piscitelli Sells 52,000 Shares - TradingView
ORIC (ORIC) CFO exercises options and sells 52,000 shares in 10b5-1 trades - Stock Titan
Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade - Finviz
Trading the Move, Not the Narrative: (ORIC) Edition - Stock Traders Daily
Q1 EPS Forecast for Oric Pharmaceuticals Raised by Analyst - MarketBeat
Oppenheimer Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC) - The Globe and Mail
ORIC: Phase III prostate cancer trial and key data updates position both programs for potential market impact - TradingView
ORIC: Phase 3 and key data updates for two oncology programs aim to drive differentiation and growth - TradingView
Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright - Yahoo Finance
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Results And Extended Cash Runway - simplywall.st
H.C. Wainwright raises ORIC Pharmaceuticals price target on trial progress - Investing.com Australia
H.C. Wainwright Maintains Buy on ORIC (ORIC Pharmaceuticals, Inc.) Feb 2026 - Meyka
Assessing ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Data And US$264 Million Capital Raise - Yahoo Finance
[144] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ORIC: Citigroup Raises Price Target to $17, Maintains Buy Rating - GuruFocus
ORIC: Citigroup Raises Price Target to $17, Maintains Buy Rating | ORIC Stock News - GuruFocus
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 7.9% Higher Following Earnings Beat - MarketBeat
ORIC Pharmaceuticals (ORIC) Sees Price Target Raised to $25 by H - GuruFocus
HC Wainwright Forecasts Strong Price Appreciation for Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat
ORIC Pharmaceuticals (ORIC) Analyst Rating Reaffirmed by Wedbush - GuruFocus
Oric Pharmaceuticals' (ORIC) "Outperform" Rating Reiterated at Wedbush - MarketBeat
Oric Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Oric Pharmaceuticals Launches New 2026 ATM Share Program - TipRanks
ArTara Therapeutics, Inc. announces that the company's research and development pipeline is progressing smoothly, and key clinical trials are advancing according to the established schedule. - Bitget
Oric Pharmaceuticals files new $200 million at-the-market offering prospectus By Investing.com - Investing.com South Africa
According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Oric Pharmaceuticals Inc. (ORIC) has announced the launch of an equity offering plan. - Bitget
Oric Pharmaceuticals files new $200 million at-the-market offering prospectus - Investing.com
ORIC's 2025 Milestones Pave Way for Future Breakthroughs - GuruFocus
ORIC Plans Key Milestones for Rinzimetostat and Enozertinib by 2 - GuruFocus
ORIC Pharmaceuticals (NASDAQ: ORIC) renews $200M ATM offering - Stock Titan
Oric Pharmaceuticals (NASDAQ:ORIC) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Oric Pharmaceuticals, Inc. SEC 10-K Report - TradingView
ORIC: Lead oncology programs advanced to late-stage trials; $245M raised; cash runway into 2028 - TradingView
ORIC Pharmaceuticals Reports Promising Phase 1b Data for Rinzimetostat and Enozertinib, Completes $264 Million Funding Round - Quiver Quantitative
ORIC Pharmaceuticals (NASDAQ: ORIC) boosts 2025 cash runway with $264M raise - Stock Titan
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates - GlobeNewswire
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 85% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Will ORIC Pharmaceuticals Inc. stock gain from government policiesWeekly Investment Summary & Capital Protection Trading Alerts - mfd.ru
Aug Highlights: What are the future prospects of ORIC Pharmaceuticals Inc2025 Institutional Moves & Daily Growth Stock Tips - baoquankhu1.vn
Venrock funds report 5.8% ORIC (ORIC) ownership stake in latest filing - Stock Titan
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25 - Defense World
(ORIC) Volatility Zones as Tactical Triggers - Stock Traders Daily
Aug Setups: What are ORIC Pharmaceuticals Incs recent SEC filings showing2025 Technical Patterns & Expert Approved Trade Ideas - baoquankhu1.vn
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Biotech Innovator with Over 105% Potential Upside - DirectorsTalk Interviews
ORIC: Lead oncology programs progress to phase III with strong funding and promising early data - TradingView
Oric Pharmaceuticals (ORIC) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):